Arrowhead Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is October - September.

Millions EUR. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Dec '25 Dec 18, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	2016 - 2020
Market Capitalization	7,900	4,064	2,159	2,721	3,568	5,616	Upgrade
Market Cap Growth	189.29%	88.24%	-20.66%	-23.72%	-36.47%	49.72%	Upgrade
Enterprise Value	7,775	3,904	2,184	2,644	3,246	5,191	Upgrade
Last Close Price	58.26	28.97	17.46	25.31	33.60	52.20	Upgrade
PS Ratio	11.17	5.75	678.12	11.96	14.38	47.07	Upgrade
PB Ratio	18.41	9.47	12.60	10.03	8.36	15.92	Upgrade
P/TBV Ratio	20.18	10.39	13.61	11.03	9.05	16.47	Upgrade
P/FCF Ratio	59.08	30.40	-	-	-	44.06	Upgrade
P/OCF Ratio	51.62	26.56	-	-	-	37.99	Upgrade
EV/Sales Ratio	10.98	5.52	686.02	11.63	13.09	43.51	Upgrade
EV/EBITDA Ratio	65.64	37.47	-	-	-	-	Upgrade
EV/EBIT Ratio	92.64	46.58	-	-	-	-	Upgrade
EV/FCF Ratio	58.14	29.20	-	-	-	40.72	Upgrade
Debt / Equity Ratio	1.46	1.46	4.46	1.34	0.20	0.06	Upgrade
Debt / EBITDA Ratio	5.29	5.29	-	-	-	-	Upgrade
Debt / FCF Ratio	4.68	4.68	-	-	-	0.17	Upgrade
Asset Turnover	0.66	0.66	0.00	0.33	0.35	0.22	Upgrade
Quick Ratio	4.73	4.73	6.57	3.75	2.67	2.58	Upgrade
Current Ratio	4.86	4.86	6.74	3.95	2.92	2.63	Upgrade
Return on Equity (ROE)	8.67%	8.67%	-254.98%	-59.33%	-42.68%	-32.36%	Upgrade
Return on Assets (ROA)	4.87%	4.87%	-39.43%	-17.58%	-15.91%	-15.11%	Upgrade
Return on Capital (ROIC)	5.39%	5.39%	-43.84%	-21.89%	-23.88%	-20.31%	Upgrade
Return on Capital Employed (ROCE)	8.30%	8.30%	-58.00%	-31.10%	-32.30%	-26.40%	Upgrade
Earnings Yield	-0.02%	-0.03%	-24.90%	-7.13%	-5.03%	-2.16%	Upgrade
FCF Yield	1.69%	3.29%	-25.10%	-11.48%	-5.40%	2.27%	Upgrade
Buyback Yield / Dilution	-11.67%	-11.67%	-12.21%	-1.26%	-1.62%	-3.00%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.